Literature DB >> 18720623

Rubella serology in pregnant women attending health centres of Tehran University of Medical Sciences.

F Majlessi1, A Batebi, M Shariat, A Rahimi, T M Azad.   

Abstract

This study was performed in 2003-05 to determine the serological status of a sample of pregnant women as a preliminary study for the rubella vaccination programme. Out of 965 pregnant women attending health centres affiliated to Tehran University of Medical Sciences for prenatal care, the estimated rubella immunity rate was 91.1% (95% CI: 89.3%-92.9%) and the nonimmunity rate was 8.9% (95% CI: 7.1%-10.7%). The rubella immunity rate differed in different areas of Tehran but not significantly so. However, there was a significant difference in the level of rubella immunity by the number of persons per household and by age, but no significant relationship with economic status, occupation or level of education.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18720623

Source DB:  PubMed          Journal:  East Mediterr Health J        ISSN: 1020-3397            Impact factor:   1.628


  3 in total

1.  Rubella seroprevalence among primary and pre- primary school pupils at Moi's Bridge location, Uasin Gishu District, Kenya.

Authors:  Janeth J Kombich; Paul C Muchai; Peter Tukei; Peter K Borus
Journal:  BMC Public Health       Date:  2009-07-29       Impact factor: 3.295

2.  Seroprevalence of anti-rubella and anti-measles IgG antibodies in pregnant women in Shiraz, Southern Iran: outcomes of a nationwide measles-rubella mass vaccination campaign.

Authors:  Behnam Honarvar; Mohsen Moghadami; Afagh Moattari; Amir Emami; Neda Odoomi; Kamran Bagheri Lankarani
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

3.  Epidemiology and aetiology of maternal bacterial and viral infections in low- and middle-income countries.

Authors:  Prasad Palani Velu; Courtney A Gravett; Tom K Roberts; Thor A Wagner; Jian Shayne F Zhang; Craig E Rubens; Michael G Gravett; Harry Campbell; Igor Rudan
Journal:  J Glob Health       Date:  2011-12       Impact factor: 4.413

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.